Gut Microbes,
Journal Year:
2025,
Volume and Issue:
17(1)
Published: April 1, 2025
Hepatocellular
carcinoma
(HCC)
remains
a
leading
cause
of
cancer-related
mortality,
with
limited
treatment
options
at
advanced
stages.
The
gut
microbiota,
diverse
community
microorganisms
residing
in
the
gastrointestinal
tract,
plays
pivotal
role
regulating
immune
responses
through
gut-liver
axis.
Emerging
evidence
underscores
its
impact
on
HCC
progression
and
efficacy
immunotherapy.
This
review
explores
intricate
interactions
between
microbiota
system
HCC,
focus
key
cells
pathways
involved
tumor
immunity.
Additionally,
it
highlights
strategies
for
modulating
–
such
as
fecal
transplantation,
dietary
interventions,
probiotics
potential
approaches
to
enhancing
immunotherapy
outcomes.
A
deeper
understanding
these
mechanisms
could
pave
way
novel
therapeutic
aimed
improving
patient
prognosis.
EBioMedicine,
Journal Year:
2024,
Volume and Issue:
100, P. 104952 - 104952
Published: Jan. 4, 2024
Gut
probiotic
depletion
is
associated
with
non-alcoholic
fatty
liver
disease-associated
hepatocellular
carcinoma
(NAFLD-HCC).
Here,
we
investigated
the
prophylactic
potential
of
Lactobacillus
acidophilus
against
NAFLD-HCC.
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: Jan. 31, 2024
The
liver
is
essential
for
metabolic
homeostasis.
onset
of
cancer
often
accompanied
by
dysregulated
function,
leading
to
rearrangements.
Overwhelming
evidence
has
illustrated
that
cellular
metabolism
can,
in
turn,
promote
anabolic
growth
and
tumor
propagation
a
hostile
microenvironment.
In
addition
supporting
continuous
survival,
disrupted
process
also
creates
obstacles
the
anticancer
immune
response
restrains
durable
clinical
remission
following
immunotherapy.
this
review,
we
elucidate
communication
between
cells
their
surrounding
discuss
how
reprogramming
impacts
microenvironment
efficacy
We
describe
crucial
role
gut-liver
axis
remodeling
crosstalk
surveillance
escape,
highlighting
novel
therapeutic
opportunities.
Signal Transduction and Targeted Therapy,
Journal Year:
2025,
Volume and Issue:
10(1)
Published: Feb. 6, 2025
Abstract
Liver
cancer
represents
a
major
global
health
concern,
with
projections
indicating
that
the
number
of
new
cases
could
surpass
1
million
annually
by
2025.
Hepatocellular
carcinoma
(HCC)
constitutes
around
90%
liver
and
is
primarily
linked
to
factors
incluidng
aflatoxin,
hepatitis
B
(HBV)
C
(HCV),
metabolic
disorders.
There
are
no
obvious
symptoms
in
early
stage
HCC,
which
often
leads
delays
diagnosis.
Therefore,
HCC
patients
usually
present
tumors
advanced
incurable
stages.
Several
signaling
pathways
dis-regulated
cause
uncontrolled
cell
propagation,
metastasis,
recurrence
HCC.
Beyond
frequently
altered
therapeutically
targeted
receptor
tyrosine
kinase
(RTK)
involved
differentiation,
telomere
regulation,
epigenetic
modification
stress
response
also
provide
therapeutic
potential.
Investigating
key
their
inhibitors
pivotal
for
achieving
advancements
management
At
present,
primary
approaches
(TKI),
immune
checkpoint
(ICI),
combination
regimens.
New
trials
investigating
therapies
involving
ICIs
TKIs
or
anti-VEGF
(endothelial
growth
factor)
therapies,
as
well
combinations
two
immunotherapy
The
outcomes
these
expected
revolutionize
across
all
Here,
we
here
comprehensive
review
cellular
pathways,
potential,
evidence
derived
from
late-stage
clinical
discuss
concepts
underlying
earlier
trials,
biomarker
identification,
development
more
effective
therapeutics
Abstract
Recent
advances
in
understanding
the
modulatory
functions
of
gut
and
microbiota
on
human
diseases
facilitated
our
focused
attention
contribution
to
pathophysiological
alterations
many
extraintestinal
organs,
including
liver,
heart,
brain,
lungs,
kidneys,
bone,
skin,
reproductive,
endocrine
systems.
In
this
review,
we
applied
“gut–X
axis”
concept
describe
linkages
between
other
organs
discussed
latest
findings
related
axis,”
underlying
mechanisms
potential
clinical
intervention
strategies.
Trends in Endocrinology and Metabolism,
Journal Year:
2024,
Volume and Issue:
35(11), P. 1006 - 1020
Published: July 5, 2024
The
gut
microbiome
can
play
a
crucial
role
in
hepatocellular
carcinoma
(HCC)
progression
through
the
enterohepatic
circulation,
primarily
acting
via
metabolic
reprogramming
and
alterations
hepatic
immune
microenvironment
triggered
by
microbe-associated
molecular
patterns
(MAMPs),
metabolites,
fungi.
In
addition,
shows
potential
as
biomarker
for
early
HCC
diagnosis
assessing
efficacy
of
immunotherapy
unresectable
HCC.
This
review
examines
how
microbiota
dysbiosis,
with
varied
functional
profiles,
contributes
to
HCCs
different
etiologies.
We
discuss
therapeutic
strategies
modulate
including
diets,
antibiotics,
probiotics,
fecal
transplantation,
nano-delivery
systems,
underscore
their
an
adjunctive
treatment
modality
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(1), P. 100 - 100
Published: Jan. 3, 2025
The
gut
microbiota,
a
dynamic
ecosystem
of
trillions
microorganisms,
produces
secondary
metabolites
that
profoundly
influence
host
health.
Recent
research
has
highlighted
the
significant
role
these
metabolites,
particularly
short-chain
fatty
acids,
indoles,
and
bile
in
modulating
immune
responses,
impacting
epigenetic
mechanisms,
contributing
to
disease
processes.
In
gastrointestinal
(GI)
cancers
such
as
colorectal,
liver,
gastric
cancer,
microbial
can
drive
tumorigenesis
by
promoting
inflammation,
DNA
damage,
evasion.
Conversely,
same
hold
therapeutic
promise,
potentially
enhancing
responses
chemotherapy
immunotherapy
even
directly
suppressing
tumor
growth.
addition,
play
crucial
roles
infectious
susceptibility
resilience,
mediating
pathways
impact
pathogen
resistance.
By
consolidating
recent
insights
into
microbiota's
shaping
health,
this
review
underscores
potential
targeting
microbiome-derived
for
treating
GI
diseases
calls
further
microbiome-based
interventions.
MedComm,
Journal Year:
2025,
Volume and Issue:
6(3)
Published: March 1, 2025
Hepatocellular
carcinoma
(HCC)
is
a
leading
cause
of
cancer-related
mortality
globally,
predominantly
associated
with
chronic
hepatitis
B
virus
(HBV)
and
C
(HCV)
infections.
These
infections
drive
persistent
liver
inflammation,
culminating
in
cellular
dysregulation,
fibrosis,
cancer.
Despite
advancements
targeted
therapies,
drug
resistance
the
lack
reliable
biomarkers
for
patient
stratification
still
terribly
hinder
treatment
viral
HCC.
To
this
end,
review
delves
into
intricate
mechanisms
underlying
malignant
transformation
to
HCC,
including
integration,
genomic
instability,
epigenetic
modifications,
oxidative
stress,
gut
microbiota
dysbiosis,
immune
escape,
abnormal
signaling
pathways,
highlighting
their
complex
interactions
synergies.
Cutting-edge
preclinical
clinical
HCC
management,
lifestyle
immunotherapies,
gene-based
approaches,
innovative
treatments,
are
further
investigated,
particular
priority
given
therapeutic
potential
future
applications
overcoming
current
limitations.
By
synthesizing
recent
scientific
insights,
aims
deepen
understanding
pathogenesis
context
hepatitis,
paving
way
novel
targets
personalized
strategies,
ultimately
improving
outcomes.
Pharmacological Research,
Journal Year:
2024,
Volume and Issue:
203, P. 107148 - 107148
Published: March 22, 2024
The
gut
microbiota,
known
as
the
"forgotten
organ"
and
"human
second
genome,"
comprises
a
complex
microecosystem.
It
significantly
influences
development
of
various
tumors,
including
colorectal,
liver,
stomach,
breast,
lung
cancers,
through
both
direct
indirect
mechanisms.
These
mechanisms
include
"gut-liver"
axis,
"lung-intestine"
interactions
with
immune
system.
intestinal
flora
exhibits
dual
roles
in
cancer,
promoting
suppressing
its
progression.
Traditional
Chinese
medicine
(TCM)
can
alter
cancer
progression
by
regulating
flora.
modifies
flora's
composition
structure,
along
levels
endogenous
metabolites,
thus
affecting
barrier,
system,
overall
body
metabolism.
actions
contribute
to
TCM's
significant
antitumor
effects.
Moreover,
microbiota
metabolizes
TCM
components,
enhancing
their
properties.
Therefore,
exploring
interaction
between
offers
novel
perspective
understanding
This
paper
succinctly
reviews
association
gastric,
cancers.
further
examines
current
research
on
flora,
focus
efficacy.
identifies
limitations
existing
studies
suggests
recommendations,
providing
insights
into
drug
effectiveness.
Additionally,
this
aims
guide
future
studies.
